Gastrointestinal Stromal Tumour (GIST) Research 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Genomic profiling in GIST: Implications in clinical outcome and future challenges
Neoplasia. 2024 Jan 5;48:100959. doi: 10.1016/j.neo.2023.100959. Online ahead of print.ABSTRACTGastrointestinal Stromal Tumors (GIST) are the most frequent mesenchymal neoplasia of the digestive tract. Genomic alterations in KIT, PDFGRA, SDH, and BRAF genes are essential in GIST oncogenesis. Therefore, the mutations in these genes have demonstrated clinical implications. Tumors with deletions in KIT-exon 11 or duplications in exon 9 are associated with a worse prognosis. In contrast, KIT-exon 11 substitutions and duplications are associated with a better clinical outcome. Moreover, mutations in Kit exon 9 and 11 are action...
Source: Neoplasia - January 6, 2024 Category: Cancer & Oncology Authors: German Calderillo-Ru íz Eloy Andr és Pérez-Yepez Mar ía Alejandra García-Gámez Oliver Millan-Catalan Consuelo D íaz-Romero Paul Ugalde-Silva Rodrigo Salas-Benavides Carlos P érez-Plasencia Berenice Carbajal-L ópez Source Type: research
Genomic profiling in GIST: Implications in clinical outcome and future challenges
Neoplasia. 2024 Jan 5;48:100959. doi: 10.1016/j.neo.2023.100959. Online ahead of print.ABSTRACTGastrointestinal Stromal Tumors (GIST) are the most frequent mesenchymal neoplasia of the digestive tract. Genomic alterations in KIT, PDFGRA, SDH, and BRAF genes are essential in GIST oncogenesis. Therefore, the mutations in these genes have demonstrated clinical implications. Tumors with deletions in KIT-exon 11 or duplications in exon 9 are associated with a worse prognosis. In contrast, KIT-exon 11 substitutions and duplications are associated with a better clinical outcome. Moreover, mutations in Kit exon 9 and 11 are action...
Source: Neoplasia - January 6, 2024 Category: Cancer & Oncology Authors: German Calderillo-Ru íz Eloy Andr és Pérez-Yepez Mar ía Alejandra García-Gámez Oliver Millan-Catalan Consuelo D íaz-Romero Paul Ugalde-Silva Rodrigo Salas-Benavides Carlos P érez-Plasencia Berenice Carbajal-L ópez Source Type: research
TRIM21/USP15 balances ACSL4 stability and the imatinib resistance of gastrointestinal stromal tumors
CONCLUSION: These findings demonstrate that the TRIM21 and USP15 control ACSL4 stability to maintain the IM sensitive/resistant status of GIST.PMID:38182686 | DOI:10.1038/s41416-023-02562-x (Source: Cancer Control)
Source: Cancer Control - January 5, 2024 Category: Cancer & Oncology Authors: Zhiwei Cui Haoyu Sun Zhishuang Gao Chao Li Tingting Xiao Yibo Bian Zonghang Liu Tianhao Gu Jianan Zhang Tengyun Li Qianzheng Zhou Zhongyuan He Bowen Li Fengyuan Li Zekuan Xu Hao Xu Source Type: research
